Figure 2.
Prevalence of MTAP-loss and 9p21 in GI cancers. (A) The prevalence of MTAP-loss by IHC in different GI cancers. (B) Coalteration rates of 9p21-loss related genes, CDKN2A and CDKN2B, in MTAP-loss and MTAP-intact. Abbreviations: PDAC, pancreatic ductal adenocarcinoma; IHCC, intrahepatic cholangiocarcinoma; CRC, colorectal carcinoma; GEAC, gastroesophageal adenocarcinoma; HCC, hepatocellular carcinoma. *P ≤ .05; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001.

Prevalence of MTAP-loss and 9p21 in GI cancers. (A) The prevalence of MTAP-loss by IHC in different GI cancers. (B) Coalteration rates of 9p21-loss related genes, CDKN2A and CDKN2B, in MTAP-loss and MTAP-intact. Abbreviations: PDAC, pancreatic ductal adenocarcinoma; IHCC, intrahepatic cholangiocarcinoma; CRC, colorectal carcinoma; GEAC, gastroesophageal adenocarcinoma; HCC, hepatocellular carcinoma. *P ≤ .05; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close